Skip to main
TRAW

Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma (TRAW) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Traws Pharma is facing a critical time as the company's Phase 2a challenge study for Tivoxavir marboxil has been halted due to MHRA setback, and with only $5.0M of cash, the company is relying on anticipated ATM proceeds to fund operations into 1Q27. Despite this challenge, the company's recent financing of up to $60M provides a cash runway to 1Q27 and allows for potential warrant exercises that could bring additional funding. The success of their bridging study in evaluating the compressed tablet formulation and MHRA approval will be crucial for the company's future growth and investors' confidence.

Bears say

Traws Pharma is a clinical-stage biopharmaceutical company with limited value in its early-stage Ebola and hantavirus program, due to uncertainty surrounding the size and durability of any commercial opportunity. With a high WACC of 19.0% and an 8.0x exit multiple, the potential for upside risks is heavily mitigated by financing, clinical trial, regulatory, delisting, and bankruptcy risks, despite potential pipeline success for COVID, hantavirus, or Ebola. Its net proceeds from sale and purchase of securities remain immaterial in terms of improving its overall outlook.

Traws Pharma (TRAW) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Traws Pharma (TRAW) Forecast

Analysts have given Traws Pharma (TRAW) a Hold based on their latest research and market trends.

According to 1 analysts, Traws Pharma (TRAW) has a Hold consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Traws Pharma (TRAW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.